Drug Trial Radar · NCT07025642
Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes
Last checked: Nov 20, 2026Latest source record: Jun 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
May 1, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Mackay Medical CollegeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 30 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Overactive bladder (OAB) syndrome is a prevalent condition that significantly impairs patients' quality of life. Standard therapeutic strategies include oral antimuscarinics (e.g., solifenacin), beta-3 adrenergic agonists (e.g., mirabegron), and intradetrusor injection of botulinum neurotoxin type A (BoNTA). Despite their clinical utility, these treatments share a common mechanism of action: suppression of detrusor muscle contractility. However, it remains unclear whether such suppression translates to a reduction in the overall mechanical work output of the bladder during micturition. To address this question, our research proposes to assess how mirabegron, solifenacin, and BoNTA influence bladder function from a thermodynamic perspective. We will apply pressure-volume analysis (PVA), a methodology traditionally used in cardiac physiology, to quantify the mechanical work performed by the bladder per voiding cycle. This approach enables a direct measurement of the energy expenditure required for bladder emptying, offering insights beyond standard urodynamic parameters. Furthermore, emerging data suggest BoNTA may exert additional effects beyond parasympathetic inhibition. Specifically, recent studies have demonstrated that BoNTA also inhibits norepinephrine release from sympathetic hypogastric nerve terminals. Since modulation of sympathetic activity-particularly via the hypogastric nerve-has been implicated in regulating bladder compliance and storage function, we hypothesize that BoNTA may influence bladder compliance through this secondary mechanism. To explore this, we will employ volume-pressure analysis (also abbreviated as PVA), which graphically represents the dynamic relationship between bladder volume and pressure throughout voiding cycles, thus capturing real-time changes in compliance. Comparative studies of mirabegron, solifenacin, and BoNTA will allow us to differentiate their respective impacts on bladder work and compliance. Mirabegron, which selectively activates beta-3 adrenergic receptors, has minimal influence on overall sympathetic tone. In contrast, solifenacin not only antagonizes muscarinic receptors but may also indirectly potentiate sympathetic tone by reducing parasympathetic influence. BoNTA, with its dual action on both autonomic pathways, provides a unique model to dissect these neural mechanisms. To extend our findings from clinical observations to preclinical validation, we aim to develop and utilize a spinal cord injury (SCI) rat model that recapitulates the bladder dysfunction observed in neurogenic detrusor overactivity (NDO)-a condition for which mirabegron, solifenacin, and BoNTA are also commonly prescribed. By applying both thermodynamic and compliance-focused PVA techniques in this animal model, we seek to construct a foundational database characterizing how these drugs modulate bladder function in a controlled, reproducible setting. In summary, this project integrates a novel application of pressure- and volume-based analyses to quantify the mechanical and compliance-related effects of established OAB therapies in both human patients and a translational animal model. The findings will provide new mechanistic insights into how these treatments alter bladder physiology, potentially guiding future therapeutic strategies and optimizing drug selection for individualized patient care.
Conditions
- Overactive Bladder (OAB)
Interventions
Urodynamic evaluation before and after solifenacin treatment.Drug
Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
Urodynamic evaluation before and after mirabegron treatment.Drug
Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
Urodynamic evaluation before and after combined treatment with solifenacin and mirabegron.Drug
Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
Urodynamic evaluation before and after Botulinum toxin (Botox) injection.Drug
Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- pressure-volume analysisTime frame: within a voiding cycle (a cycle is about 30 to 60 minutes) 1-4 weeks before and 6-12 month after the operation
- volume-pressure analysisTime frame: within a voiding cycle (a cycle is about 30 to 60 minutes) 1-4 weeks before and 6-12 month after the operation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Obstetrics and Gynecology
New Taipei City, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.